GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET - النمو ، والاتجاهات ، وتأثير COVID-19 ، والتوقعات (2022 - 2027)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Deliverables

   2. 1.2 Study Assumptions

   3. 1.3 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Drivers

   3. 4.3 Restraints

   4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Drug

      1. 5.1.1 Exenatide

         1. 5.1.1.1 Byetta (Value and Volume 2012-2024)

         2. 5.1.1.2 Bydureon (Value and Volume 2012-2024)

      2. 5.1.2 Liraglutide

         1. 5.1.2.1 Victoza (Value and Volume 2012-2024)

      3. 5.1.3 Lixisenatide

         1. 5.1.3.1 Lyxumia (Value and Volume 2012-2024)

      4. 5.1.4 Dulaglutide

         1. 5.1.4.1 Trulicity (Value and Volume 2012-2024)

   2. 5.2 Geography

      1. 5.2.1 North America

         1. 5.2.1.1 US (Value and Volume 2012-2024)

            1. 5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.1.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         2. 5.2.1.2 Canada (Value and Volume 2012-2024)

            1. 5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.1.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         3. 5.2.1.3 Rest of North America (Value and Volume 2012-2024)

            1. 5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.1.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

      2. 5.2.2 Europe

         1. 5.2.2.1 Germany (Value and Volume 2012-2024)

            1. 5.2.2.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.2.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         2. 5.2.2.2 Spain (Value and Volume 2012-2024)

            1. 5.2.2.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.2.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         3. 5.2.2.3 Italy (Value and Volume 2012-2024)

            1. 5.2.2.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.2.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         4. 5.2.2.4 France (Value and Volume 2012-2024)

            1. 5.2.2.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.2.4.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         5. 5.2.2.5 UK (Value and Volume 2012-2024)

            1. 5.2.2.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.2.5.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         6. 5.2.2.6 Russia (Value and Volume 2012-2024)

            1. 5.2.2.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.2.6.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         7. 5.2.2.7 Rest of Europe (Value and Volume 2012-2024)

            1. 5.2.2.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.2.7.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

      3. 5.2.3 Asia-Pacific

         1. 5.2.3.1 Japan (Value and Volume 2012-2024)

            1. 5.2.3.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         2. 5.2.3.2 China (Value and Volume 2012-2024)

            1. 5.2.3.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         3. 5.2.3.3 Australia (Value and Volume 2012-2024)

            1. 5.2.3.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         4. 5.2.3.4 India (Value and Volume 2012-2024)

            1. 5.2.3.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.4.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         5. 5.2.3.5 South Korea (Value and Volume 2012-2024)

            1. 5.2.3.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.5.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         6. 5.2.3.6 Malaysia (Value and Volume 2012-2024)

            1. 5.2.3.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.6.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         7. 5.2.3.7 Indonesia (Value and Volume 2012-2024)

            1. 5.2.3.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.7.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         8. 5.2.3.8 Thailand (Value and Volume 2012-2024)

            1. 5.2.3.8.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.8.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         9. 5.2.3.9 Philippines (Value and Volume 2012-2024)

            1. 5.2.3.9.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.3.9.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         10. 5.2.3.10 Rest of Asia-Pacific (Value and Volume 2012-2024)

             1. 5.2.3.10.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

             2. 5.2.3.10.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

      4. 5.2.4 Latin America

         1. 5.2.4.1 Brazil (Value and Volume 2012-2024)

            1. 5.2.4.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.4.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         2. 5.2.4.2 Mexico (Value and Volume 2012-2024)

            1. 5.2.4.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.4.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         3. 5.2.4.3 Rest of Latin America (Value and Volume 2012-2024)

            1. 5.2.4.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.4.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

      5. 5.2.5 Middle East & Africa

         1. 5.2.5.1 South Africa (Value and Volume 2012-2024)

            1. 5.2.5.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.5.1.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         2. 5.2.5.2 Saudi Arabia (Value and Volume 2012-2024)

            1. 5.2.5.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.5.2.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         3. 5.2.5.3 Oman (Value and Volume 2012-2024)

            1. 5.2.5.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.5.3.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         4. 5.2.5.4 Egypt (Value and Volume 2012-2024)

            1. 5.2.5.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.5.4.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         5. 5.2.5.5 Iran (Value and Volume 2012-2024)

            1. 5.2.5.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.5.5.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

         6. 5.2.5.6 Rest of Middle East & Africa (Value and Volume 2012-2024)

            1. 5.2.5.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

            2. 5.2.5.6.2 By Company (NovoNordisk, Sanofi, Eli Lilly, and AstraZeneca)

6. 6. MARKET INDICATORS

   1. 6.1 Type-1 Diabetes Population (2012-2024)

   2. 6.2 Type-2 Diabetes Population (2012-2024)

7. 7. COMPETITIVE LANDSCAPE

   1. 7.1 COMPANY PROFILES

      1. 7.1.1 NovoNordisk

      2. 7.1.2 Sanofi

      3. 7.1.3 Eli Lilly

      4. 7.1.4 AstraZeneca

   2. 7.2 MARKET SHARE ANALYSIS

      1. 7.2.1 NovoNordisk

      2. 7.2.2 Sanofi

      3. 7.2.3 Eli Lilly

      4. 7.2.4 AstraZeneca

8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS